Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Aswartha Pothula

Interventional Cardiology Moline, IL Medical Doctor

NPI 1497734396 CMS profile 405588

1100 36Th Avenue, Moline, IL 61265

Open in the dashboard

General payments

$471

16 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,000 paid to institutions, not to them · program year 2019

Through program year 2023, Aswartha Pothula of Moline, IL is reported in the CMS Open Payments database as having received $471 across 16 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $9,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 8th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $41 2
2022 General $206 7
2020 General $145 2
2019 General $79 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aswartha Pothula
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Aswartha Pothula were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Aswartha Pothula Interventional Cardiology median Middle half National median
2019 $79 $1,097 $329–$3,048 $163
2020 $145 $473 $161–$1,480 $114
2021 $0 $677 $233–$1,827 $132
2022 $206 $978 $333–$2,724 $149
2023 $41 $1,136 $382–$2,986 $160
2024 $0 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Astellas Pharma US Inc $245 3 payments
  2. AstraZeneca Pharmaceuticals LP $60 4 payments
  3. Sanofi-Aventis U.S. LLC $55 3 payments
  4. Edwards Lifesciences Corporation $31 1 payment
  5. Abbott Laboratories $19 1 payment
  6. Novartis Pharmaceuticals Corporation $18 1 payment
  7. Bayer HealthCare Pharmaceuticals Inc. $16 1 payment
  8. Merck Sharp & Dohme Corporation $15 1 payment
  9. Janssen Pharmaceuticals, Inc $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Education $245 3 payments
  2. Food and Beverage $226 13 payments
Products named General payments · program years 2019–2023
  1. BRILINTA $60 4 payments
  2. MULTAQ $55 3 payments
  3. HemoSphere $31 1 payment
  4. Hi-Torque Balance guide wires $19 1 payment
  5. LEQVIO $18 1 payment
  6. Kerendia $16 1 payment
  7. VERQUVO $15 1 payment
  8. XARELTO $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

14,674

Median for Interventional Cardiology: 2,236

Drug cost

$1,942,237

Median for Interventional Cardiology: $380,412

Branded share of claims

35.1%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 849 $921,895
Entresto Sacubitril/Valsartan Brand 371 $420,942
Xarelto Rivaroxaban Brand 117 $136,271
Brilinta Ticagrelor Brand 157 $128,588
Repatha Sureclick Evolocumab Brand 75 $61,524
Multaq Dronedarone Hcl Brand 28 $34,512
Ranolazine Er Ranolazine Brand 270 $29,733
Metoprolol Succinate Generic 2,369 $29,192
Jardiance Empagliflozin Brand 18 $23,456
Clopidogrel Clopidogrel Bisulfate Brand 1,350 $16,528

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 121 billing codes

Paid by Medicare

$1,120,957

Of which drugs: $8,991

Medicare patients

3,373

Average age 76

Services billed

26,172

1,725 women, 1,648 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 57%
Arthritis 50%
Chronic kidney disease 35%
Diabetes 34%
Atrial fibrillation 33%
Heart failure 29%
COPD 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 338 1,356 $6,642
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 161 15,965 $1,612
Injection, perflutren lipid microspheres, per ml Q9957 Office 12 24 $732

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

16 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record